



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.	:	09/510,562	Confirmation No.:	3061
Applicant	:	Gerard M. Housey		
Filed	:	February 22, 2000		
TC/A.U.	:	1636		
Examiner	:	Guzo, D.		
Docket No.	:	395/35		
Customer No.	:	23838		

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Declaration of James D. Griffin, M.D. Under 37 C.F.R. § 1.132

SIR:

I, James D. Griffin, M.D., hereby declare and state as follows:

1. I am a Professor of Medicine at Harvard Medical School. I am Chairman of the Department of Medical Oncology at the Dana-Farber Cancer Institute as well Professor of Medicine at Harvard Medical School. I am the Director of the Leukemia Program at the Dana-Farber/Harvard Cancer Center. I also serve on the External Advisory Board of Johns Hopkins Hospital Cancer Center and the Lombardi Cancer Center of Georgetown University Medical Center. I received a Bachelor of Arts degree and a Master of Medical Science degree from Brown University in 1970 and 1972 respectively, and a Doctor of Medicine degree from Harvard Medical School in 1974. A copy of my *curriculum vitae* has been designated Exhibit A.

2. At various times from 1984 to the present, I have been on the Editorial Boards of *Blood*; *Leukemia Research*; *Experimental Hematology*; *Leukemia*; and *British Journal of Hematology*, have been an Associate Editor of *Hematological Oncology* and *Blood* and have served as Editor-in-Chief of *Blood*. Most of the research I have performed in my more than

served as Editor-in-Chief of *Blood*. Most of the research I have performed in my more than twenty five years in medicine has involved the general areas of hematology and oncology, including the study of regulation of hematopoiesis, the biology of myeloid leukemias, and the function of hematopoietic growth factors. In the course of my career, I have authored or coauthored numerous articles that deal specifically with regulation of cellular biological functions, including aberrant expression of cellular proteins and interactions of cell surface receptors and their ligands.

3. I have provided expert testimony and declarations for Housey Pharmaceuticals, Inc. in the past and have worked with Kenyon & Kenyon on other patent-related matters.

4. In my opinion, one of ordinary skill in the art relevant to this subject matter would have an advanced degree in a biomedical field of science, such as medicine, cell biology, molecular biology, immunology, or a related field, and at least one or two years of additional research experience.

5. Housey's invention is directed to a method of determining whether a substance is an inhibitor or activator of a particular protein. Prior to Housey, methods of finding modulators of cellular functions using different types of assays were known. Specification, page 1, lines 12-19. Such assays would necessarily find inhibitors or activators of proteins or other cellular components albeit in a non-specific manner because any substance (*i.e.*, any agent) which altered the function, *i.e.*, the phenotypic characteristic under examination, would be detected. For example, an agent which inhibits the growth properties of cells or which inhibits cellular growth "in any way" scores positive in a cell-based assay for colony formation in soft agar but has not necessarily targeted a protein of interest ("POI"). *Id.* at page 2, lines 8-10, 25-27; page 3, lines 9-12.

6. Housey's improvement over the prior art assays was to provide a method of screening using a cell-based assay to identify inhibitors or activators which are specific for a particular protein. Specification, page 3, line 31 to page 4, line 4. Housey's claimed method requires that the POI be overproduced in a test cell and, under appropriate culture conditions, that such expression leads to a change in a phenotypic characteristic of the test cell other than the level of the POI *per se* (relative to a control), *i.e.*, that production of the protein in the test cell evokes a responsive change in a phenotypic characteristic other than the level of the protein in the cell *per se*. It is this identified phenotypic response that is then used to search for inhibitors or activators of the POI.

7. The Housey method requires a specific type of change in a phenotypic characteristic of the cell. Housey requires that the changed phenotypic characteristic arise from activity of the protein as it functions in the cell and not from the mere presence of the protein in the cell. Without this feature, there could be no specificity in Housey's method of identifying substances which directly and specifically stimulate or inhibit the activity of a protein (the POI) by monitoring changes in a phenotypic characteristic in response to the substance.

8. The specific change in a phenotypic characteristic and the sensitivity of that phenotypic characteristic is dependent on the cell's production of the POI. According to the method, test cells are generated that stably overproduce the POI. Under appropriate growth conditions, the cells exhibit a "graded cellular response" to activators or inhibitors of the POI. Specification, page 4, lines 13-16; page 4, line 35 to page 5 line 2.

9. A graded cellular response is a phenotypic change exhibited by a cell which becomes greater with increasing expression of the POI. Specification, page 12, lines 22-28. For example, where an observable phenotypic change is growth in soft agar, there is a graded cellular response if a relatively low level of the POI results in relatively small changes in growth in soft

agar by modulators of the POI whereas a relatively high level of the POI results in relatively large changes in growth in soft agar by modulators of the POI. The phenotypic change is responsive to the level of the protein.

10. I am familiar with the Office Action mailed October 5, 2005, including the reasons set forth by the Examiner in support of his conclusion that the specification does not enable a person skilled in the art to which it pertains to practice the claimed invention because undue experimentation would be required in order to sort out whether a test agent is a direct inhibitor or activator of the POI or is exerting its effect on the observed phenotypic changes by some other (indirect) mechanism. Based on my knowledge of and experience in the cell biology field, I respectfully disagree based on the following.

11. Housey's specification teaches that a useful graded cellular response can be provided by stable overexpression of a POI. Housey's specification demonstrates that in the example where the POI is the β isoform of protein kinase C, inhibitors of protein kinase C reduce the phenotypic change in the cells in a graded manner. Using the same specialized phenotype, the specification also demonstrates that tamoxifen is a direct inhibitor of protein kinase C.

12. Housey's identification and use of a graded cellular response enables one of ordinary skill in the art to identify substances which are modulators of the POI that evokes the graded cellular response. This specific type of change in a phenotypic characteristic allows the identification of modulators that act directly on the POI instead of modulators that act on other cellular components.

13. One of ordinary skill in the art would be able to identify activators and inhibitors of a POI by the methods disclosed by Housey. Since the time of Housey's invention, stable overproduction of a POI has become an established means for distinguishing the effect of modulators of a POI on a phenotype from confounding effects of other cellular components.

14. The Examiner has cited certain references to illustrate the complex and unpredictable nature of signaling pathways and how use of phenotypic changes associated with expression of a target enzyme (POI) in a method for identifying direct inhibitors or activators of the POI can actually result in identification of agents which do not interact with the target but instead interact with another component of the cell. Whatever complexity and unpredictability is ascribed to other methods in the art that employ phenotypic changes in cells or seek to identify inhibitors or activators of a POI cannot be used to evaluate Housey's method because Housey's method is different from that art. In fact, Housey's method operates in the face of such complexities. One of ordinary skill would recognize the difference between Housey's invention and such methods. Further, one of ordinary skill with knowledge of Housey's invention, upon practicing the methods disclosed in the articles would not be misled into thinking that activators or inhibitors obtained by such methods were direct (specific) activators or inhibitors of the POI.

15. Hsiao et al., Mol. Cell. Biol., 1986, Vol. 6, No. 6, pp. 1943-1950 (Hsiao) has been cited as evidence of unpredictability of the claimed invention. The method employed by Hsiao lacks critical elements of the claimed invention because no correlation is made between p21^{ras} function and p21^{ras} level. To make such a correlation, Hsiao would need to isolate individual cell lines and characterize the level of p21^{ras} in those cell lines. However, Hsiao did not isolate any individual cell lines or characterize the level of p21 present in any cell lines, much less correlate the level of p21^{ras} with any function or phenotype of the cell line. Hsiao neither identifies, nor makes use of a "graded cellular response" or any other responsive change in a phenotypic characteristic. Hsiao's method does not rely on any association between POI level and phenotype that would enable one of ordinary skill to predictably identify compounds that directly activate or inhibit p21^{ras}.

16. In my opinion, one of ordinary skill in the art, having read Housey's specification, would not be misled by Hsiao's article into believing that any substance tested according to Hsiao's method was a direct activator or inhibitor of a POI. This is because Housey's method critically associates the level of the POI in a cell with a responsive phenotypic change. Hsiao does not.

17. Ledwith et al., Mol. Cell. Biol., 1990, Vol. 10, No. 4, pp. 1545-1555 (Ledwith) has also been cited as evidence of unpredictability. It was contended that if one of ordinary skill in the art used Housey's method to attempt to identify an inhibitor of p21^{ras} and the test compound actually directly bound to and inhibited *c-fos*, the compound would erroneously be identified as an inhibitor of p21^{ras}. Ledwith has not made use of a "graded cellular response" or any other responsive change in a phenotypic characteristic. Accordingly, one of ordinary skill in the art, seeing the type of inhibition observed by Ledwith would not conclude that a compound causing such an effect was a direct inhibitor of p21^{ras}.

18. A responsive change in a phenotypic characteristic of a cell is a phenotypic characteristic that is responsive to inhibitors or activators of a given protein. A graded cellular response is an increase in the phenotypic change exhibited by the cell which becomes greater with increasing expression of the POI. Specification, page 12, lines 22-28. Ledwith has not established any correlation between the level of expression of p21^{ras} and a responsive change in a phenotypic characteristic. Ledwith has only established a relationship between a protein in a cell that is not the POI (not the level of that protein) and the level of a compound that reduces the amount of that protein. Because a responsive change in a phenotypic characteristic of the p21^{ras} overexpressing cells has not been defined, the effect of any compound (chemical, antisense RNA, or otherwise) cannot be evaluated according Housey's claimed method. To reach any


Appl. No. 09/510,562

Declaration of James D. Griffin, M.D.

conclusion as to direct or indirect inhibition, Ledwith at least would need to evaluate terminal cell density as a function of p21^{ras} level.

19. In my opinion, one of ordinary skill in the art, having read Housey's specification, would not be misled by Ledwith's article into believing that any substance tested according to Ledwith's method was a direct activator or inhibitor of a POI. This is because Housey's method critically associates the level of the POI in a cell with a responsive phenotypic change.

Date 4/5/06


James D. Griffin, M.D.

CURRICULUM VITAE

James D. Griffin, M.D.

Address: 156 Dean Road, Brookline, MA 02445

Date of Birth: March 17, 1948

Place of Birth: Cortland, New York

Education:

1970	A.B.	Brown University, Providence, RI
1972	M.M.S.	Brown University, Providence, RI
1974	M.D.	Harvard Medical School, Boston, MA

Postdoctoral Training:

Internship and Residencies:

1974 - 1975	Intern in Medicine, John Hopkins Hospital, Baltimore, MD
1975 - 1976	Resident in Medicine, John Hopkins Hospital, Baltimore, MD

Research and Clinical Fellowships:

1976 - 1977	Clinical and Research Fellow in Hematology, Massachusetts General Hospital, Boston, MA
1977 - 1979	Research Fellow in the Division of Tumor Virology, Dana-Farber Cancer Institute, Boston, MA
1979 - 1980	Clinical Fellow in Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

Licensure and Certification:

1976	Massachusetts License No. 39416
1977	American Board of Internal Medicine, Certificate No. 59329
1978	Hematology Subspecialty, ABIM, Certificate No. 59329
1981	Medical Oncology Subspecialty, ABIM Certificate No. 59329

Academic Appointments:

1980 - 1981	Instructor in Medicine, Harvard Medical School, Boston, MA
1981 - 1985	Assistant Professor of Medicine, Harvard Medical School, Boston, MA
1985 - 1993	Associate Professor of Medicine, Harvard Medical School, Boston, MA
1993-	Professor of Medicine, Harvard Medical School, Boston, MA

Hospital Appointments:

1980 - 1981	Clinical Associate, Dana-Farber Cancer Institute
1980 - 1982	Junior Associate in Medicine, Brigham and Women's Hospital, Boston, MA
1981 - 1985	Assistant Physician, Dana-Farber Cancer Institute, Boston, MA
1982 -	Associate Physician, Brigham & Women's Hospital, Boston, MA
1983 -	Consultant Physician (Hematology/Oncology) Boston Veterans Administration Hospital
1985 -1993	Associate Physician, Dana-Farber Cancer Institute, Boston, MA
1993-	Attending Physician, Dana-Farber Cancer Institute, Boston, MA

Awards and Honors:

1969	Sigma Xi
1974	Alpha Omega Alpha
1978 - 1977	Damon Runyon-Walter Winchell Fellow
1981 - 1982	Johanna C. Woods Foundation Fellow
1982 - 1983	Medical Foundation Fellow
1985 - 1990	Scholar, Leukemia Society of America
1989	American Society of Clinical Investigation
1993	Mario Baldini Visiting Professor of Hematology, New England Deaconess Hospital, Boston, MA
1995-	External Advisory Board, Lombardi Cancer Center, Georgetown University Medical Center
1998-	External Advisory Board, Johns Hopkins Hospital Cancer Center
2000-	Principal Investigator, Specialized Center of Excellence
Award,	Leukemia and Lymphoma Society
2000-	National Board of Trustees, Leukemia and Lymphoma Society
Society	
2001	Dr. Anthony D. Cortese Award, Leukemia and Lymphoma Society of America
2001	Elected to Association of American Physicians
2001-	National Trustee, Leukemia and Lymphoma Society
2003-	External Advisory Board, Case Western Cancer Center

Major Committee Assignments:

Editorial:

1984 - 1988	Editorial Board, <u>Blood</u>
1984 - 1987	Editorial Board, <u>Leukemia Research</u>
1987 - 1990	Editorial Board, <u>Experimental Hematology</u>
1987 -	Editorial Board, <u>Leukemia</u>
1988 -	Associate Editor, <u>Hematological Oncology</u>
1988 - 1993	Associate Editor, <u>Blood</u>
1993 - 1998	Editor-in-Chief, <u>Blood</u>
1998-	Editorial Board, <u>British Journal of Hematology</u>
2000-	Editorial Board, <u>Journal of Hematotherapy & Stem Cell Research</u>

NIH:

1989 - 1993	NIH Study Section Member, Hematology 1
1990-	Ad hoc reviewer, NIH Hematology 1 Study Section and various PPG reviews
2000	Co-chair, Biology Roundtable, Progress Review Group, Leukemia, Lymphoma and Myeloma, National Cancer Institute

Dana Farber Cancer Institute:

1981 - 1989	Medical Oncology Fellowship Selection Committee
1982 - 1991	Transfusion Committee
1982 - 1984	Clinical Data Processing Committee
1983 - 1986	Bylaws Committee
1983 - 1990	Biomedical Research Support Grant Review Committee
1984 - 1986	Secretary, Medical Staff
1986 - 1987	President, Medical Staff
1990 - 1997	Scientific Review Committee
1995- 1997	Medical Executive Committee (Promotions)
1996- 1997	Research Promotions Committee
1997- 2002	Vice Chair for Research, Dept of Adult Oncology
1996- 1998	Executive Committee for Research
2001-	Executive Committee for Research
1996- 1998	Vice Chairman, Faculty Research Council
1997-	DFCI Institutional Promotions Committee
2001-	Promotions Committee, Dept of Adult Oncology
2001- 2002	Adult Oncology Executive Steering Committee
2002-	Chairman, Department of Medical Oncology, DFCI
2002-	Chief, Division of Medical Oncology, Brigham and Women's Hospital

Membership, Offices, and Committee Assignments in Professional Societies

1980 -	American Society of Hematology
1983 - 1986	Scientific Subcommittee on Leukocyte Physiology, ASH
1984 -	American Society of Clinical Oncology

1984 -	International Society of Experimental Hematology
1984 -	American Association of Immunologists
1984	Co-Director (Myeloid Section), Second International Workshop on Human Leukocyte Differentiation Antigens, Boston, MA, 17-20 September.
1985 - 1987	Scientific Subcommittee on Leukocyte Physiology, ASH
1987 - 1990	Scientific Subcommittee on Hematopoietic Growth Factors, ASH
1988 -	Public Relations Committee (Cytokines), ASCO
1989 -	American Society for Clinical Investigation
1991 -	American Society for Cancer Research
1993-1997	ASH Executive Committee
1993-1997	ASH Publication Committee
1993-1995	ASH Program Committee
1995	Chairman, Scientific Program, ASH
1998-2001	Chairman, Scientific Subcommittee on Hematopoietic Growth Factors, ASH
1998-	Scientific Committee, Leukemia Society of America
1998-2003	Advisory Board, American Society of Hematology
1999	Strategic Planning Committee, International Society of Hematology
1999-2003	Chairman, Publications Committee, International Society for Experimental Hematology
2000-	ASH Editor Selection Committee
2000-	ASCI Editor Selection Committee
2001- 2002	Chair, Experimental Hematology Editor Selection Committee, ISEH

Major Research Interests:

1. Regulation of hematopoiesis
2. Biology of myeloid leukemias
3. Leukemia oncogenes as targets for drug development
4. Notch receptor function

Teaching Experience:

1976 - 1977	Research and clinical seminars in Hematology, Massachusetts General Hospital
1977 - 1979	Taught course in Laboratory Hematology, University of Lowell
1978 - 1980	Supervision of a student laboratory research project on tumor virus proteins
1978 - 1980	Research seminars on tumor virus proteins and viral transformation.
1979 -	Supervision and didactic instruction of medical residents, interns, and medical students; lectures and seminars on Clinical Oncology, Dana Farber Cancer Institute

1980 -	Research seminars on myeloid leukemia antigens
1981 -	Consultation clinic, Dana-Farber Cancer Institute
1982 -	Lectures in Harvard Tumor Cell and Molecular Biology Course
1983 -	Lecturer in HMS Immunology 713.7/209 (Tumor Immunology)
1982, 1983	American Society of Hematology Educational Session, "Clinical Application of Immune Markers and Monoclonal Antibodies"
1984, 1986	Faculty, HMS Hybridomas in Biotechnology and Medicine Course
1985	Faculty, HMS Cancer Medicine Course
1987	Faculty, HMS Cancer Medicine Course
1988	Faculty, HMS Course, "Intensive review of Hematology and Hematologic Oncology."
1993-present	Faculty, HMS Cancer Medicine Course

Clinical and Hospital Service Responsibilities

1979 -	Medical Oncology Clinic, Dana-Farber Cancer Institute
1981 -	Attending Physician, Medical Oncology Service, Dana-Farber Cancer Institute
1981 -1993	Consultation Clinic, Dana-Farber Cancer Institute
1996-1997	Chief, Division of Hematologic Malignancies
1998- 2002	Director, Leukemia Program, Dana-Farber/Harvard Cancer Center
2002-	Chair, Department of Medical Oncology, DFCI, and Chief, Division of Medical Oncology, Brigham and Women's Hospital, Boston.

BIBLIOGRAPHY

Original Reports

1. **Griffin JD**, Szaro RP, Weltman JK. Ouabain antagonism of smooth muscle contraction. *J Pharm Exp Med* 1972; 182:378-7
2. Coleman AW, Coleman JP, **Griffin JD**, Weltman JK, Chapman KM. Methylxanthine induced escalation: A propagated wave phenomenon observed in skeletal muscle developing in culture. *Proc Natl Acad Sci USA* 1972; 69:613-6.
3. Rawling W, **Griffin JD**, Duffy T, Humphrey R. Fanconi syndrome with lambda light chains in the urine. *New Eng J Med* 1975; 292:1351.
4. **Griffin JD**, Ellman L, Long JC, Dvorak AM. Development of a histiocytic medullary reticulosis-like syndrome in the course of acute lymphocytic leukemia. *Am J Med* 1978; 64:851-7.
5. **Griffin JD**, Aisenberg A, Long JC. Lymphocytic thymoma associated with T-cell lymphocytic leukemia. *Am J Med* 1978; 64:1075-80.
6. **Griffin JD**, Light S, Livingston DM. Measurements of the molecular size of the Simian virus 40 large T antigen. *J Virol* 1978; 27:218-26.
7. Kriegler MK, **Griffin JD**, Livingston DM. Phenotypic complementation of the SV40 tsA mutant defect in viral DNA synthesis following microinjection of SV40 T antigen. *Cell* 1978; 14:983-8.
8. **Griffin JD**, Ellman L. Epsilon aminocaproic acid. *Semin Thrombosis Hemostasis*. 1978; 5:27-40.
9. **Griffin JD**, Spangler GJ, Livingston DM. Protein kinase activity associated with Simian virus 40 T antigen. *Proc Natl Acad Sci USA* 1979; 76:2610-4.
10. Spangler GJ, **Griffin JD**, Rubin H, Livingston DM. Identification and initial characterization of a new low molecular weight virus-encoded T antigen in a line of Simian virus 40-transformed cells. *J Virol* 1980; 36:488-98.
11. **Griffin JD**, Spangler GJ, Livingston DM. Enzymatic activities associated with the SV40 large T antigen. *Cold Spring Harbor Symp; Quant Biol Vol XLIV*: 1980; 113-22.
12. Bradley MK, **Griffin JD**, Livingston DM. Phosphotransferase activities associated with large T antigen. *Cold Spring Harbor Conferences on Cell Proliferation*. 1981; 8:1263-71.
13. Major PP, **Griffin JD**, Minden M, Kufe DW. A blast subline of the HL60 cell line. *Leuk Res* 1981; 5:429-30.

14. Todd RF, **Griffin JD**, Ritz J, Nadler LM, Abrams T, Schlossman SF. Expression of normal monocyte-macrophage differentiation antigens on HL60 promyelocytes undergoing differentiation induced by leukocyte-conditioned medium or phorbol diester. *Leuk Res* 1981; 5:491-5.
15. **Griffin JD**, Ritz J, Nadler LM, Schlossman SF. Expression of myeloid differentiation antigens on normal and malignant myeloid cells. *J Clin Invest* 1981; 68:932-41.
16. **Griffin JD**, Garnick MJ. Eye toxicity of cancer chemotherapy. *Cancer* 1981; 48:1539-49.
17. Nadler LM, Ritz J, **Griffin JD**, Todd RF, Reinherz EL, Schlossman SF. Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies. *Prog Hematol* 1981; 12:187-225.
18. Posner MR, Antoniou D, **Griffin JD**, Schlossman SF, Lazarus H. An enzyme-linked immunosorbent assay (ELISA) for the detection of monoclonal antibodies to cell surface antigens on viable cells. *J Immunol Methods* 1982; 48:23-31.
19. Bradley MK, **Griffin JD**, Livingston DM. Oligomerization and nucleotide binding properties of the SV40 large T antigen. *Cell* 1982; 28:125-34.
20. **Griffin JD**, Beveridge RP, Schlossman SF. Isolation of myeloid progenitor cells from peripheral blood of chronic myelogenous leukemia patients. *Blood* 1982; 60:30-7.
21. **Griffin JD**, Major PP, Monroe D, Kufe D. Induction of differentiation of human myeloid leukemia cells by inhibitors of DNA synthesis. *Exp Hematol* 1982; 10:774-81.
22. **Griffin JD**, Todd RF, Ritz J, Nadler LM, Canellos GP, Rosenthal DS, Gallivan MEV, Beveridge RP, Weinstein HJ, Karp D, Schlossman SF. Differentiation patterns in the blastic phase of chronic myeloid leukemia. *Blood* 1983; 61:85-91.
23. **Griffin JD**, Ritz J, Beveridge RP, Lipton JM, Daley JF, Schlossman SF. Expression of MY7 antigen on human hematopoietic stem cells: Identification of subpopulation of myeloid precursor cells. *Int J Cell Cloning* 1983; 1:33-48.
24. **Griffin JD**, Canellos GP, Reinherz EL, Wisch JS, Sherwood G, Beveridge RP, Daley JF, Lane H, Schlossman SF. T cell surface antigens in a patient with blast crisis of chronic myeloid leukemia. *Blood* 1983; 61:640-3.
25. **Griffin JD**, Hercend T, Beveridge RP, Schlossman SF. Characterization of an antigen expressed by human natural killer cells. *J Immunol* 1983; 130:2947-52.
26. Minden M, Major P, Griffin J, Wu A, Kufe D. Generation time of leukemic blast progenitor cells. *Cell Tiss Kinetics* 1983; 16:577-82.

27. Garnick MB, **Griffin JD**. Association of idiopathic thrombocytopenia with extragonadal germ cell cancer. *Ann Int Med* 1983; 98:926-7.
28. Weiss RB, Moquin D, Adams JD, **Griffin JD**, Zimble H. Electrocardiogram abnormalities induced by amsacrine. *Cancer Chemother Pharmacol* 1983; 10:133-4.
29. Hokland P, Rosenthal P, **Griffin JD**, Nadler LM, Daley J, Hokland M, Schlossman SF, Ritz J. Purification and characterization of fetal hematopoietic cells which express the common acute lymphoblastic antigen (CALLA). *J Exp Med* 1983; 157:114-29.
30. Letvin NL, Todd RF, Palley LS, Schlossman SF, **Griffin JD**. Conservation of myeloid surface antigens on primate granulocytes. *Blood* 1983; 61:408-10.
31. Anderson KC, **Griffin JD**, Bates MP, Slaughenhaupt B, Schlossman SF, Nadler LM. Isolation and characterization of human B lymphocyte enriched populations. *J Immunol Methods* 1983; 61:283-92.
32. Rosenthal P, Rimm IJ, Umiel T, **Griffin JD**, Osathanondh R, Schlossman SF, Nadler LM. Ontogeny of human hematopoietic cells: Analysis utilizing monoclonal antibodies. *J Immunol* 1983; 131:232-7.
33. **Griffin JD**, Beveridge RP, Schlossman SF. Effect of phorbol ester on differentiation of human myeloid colony forming cells. *Leuk Res* 1983; 7:43-9.
34. **Griffin JD**, Mayer RJ, Weinstein HJ, Rosenthal DS, Coral FS, Beveridge RP, Schlossman SF. Surface marker analysis of acute myeloblastic leukemia: Identification of differentiation-associated phenotypes. *Blood* 1983; 62:557-63.
35. Wisch JS, **Griffin JD**, Kufe DW. Preleukemic syndromes respond to low dose continuous infusion cytarabine. *New Engl J Med* 1983; 309:1599-1602.
36. Tantravahi R, **Griffin JD**, Henkle, Leavitt PR, Mayer RJ, Frei E. Immunological and cytogenetic studies in two cases of B-cell acute lymphoblastic leukemia (Burkitt's type). *Cancer Genetics Cytogenetics* 1983; 5:167-75.
37. **Griffin JD**, Larcom P, Schlossman SF. Use of surface markers to identify a subset of acute myelomonocytic leukemia cells with progenitor cell properties. *Blood* 1983; 62:1300-3.
38. **Griffin JD**, Sullivan R, Beveridge RP, Larcom P, Schlossman SF. Induction of proliferation of purified human myeloid progenitor cells: A rapid assay for granulocyte colony stimulating factors. *Blood* 1984; 63:904-11.
39. Hokland P, **Griffin JD**, Nadler LM, Schlossman SF, Ritz J. Purification of common acute lymphoblastic leukemia (CALLA) positive cells from normal bone marrow. *Blood* 1984; 64:662-6.

40. **Griffin JD**, Linch DC, Sabbath K, Schlossman SF. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. *Leukemia Res* 1984; 8:521-4.
41. Tantravahi R, Schwenn M, Hanble C, Nell M, Leavitt PR, **Griffin JD**, Weinstein HJ. A pericentric inversion of chromosome 16 is associated with dysplastic marrow eosinophils in acute myelomonocytic leukemia. *Blood* 1984; 63:800-2.
42. Sugiura M, Schafman T, Mitchell T, Griffin J, Kufe D. Involvement of spermidine in proliferation and differentiation of human promyelocytic leukemia cells. *Blood* 1984; 63:1153-8.
43. Munroe D, Sugiura M, Griffin J, Kufe D. Effect of Ara-A on differentiation and proliferation on HL-60 cells. *Leukemia Res* 1984; 8:355-61.
44. **Griffin JD**, Meuer SC, Schlossman SF, Reinherz EL. T cell regulation of myelopoiesis: Analysis at a clonal level. *J Immunol* 1984; 135:1863-88.
45. Kufe DW, **Griffin JD**, Mitchell T, Shafman T. Polyaminees are required for induction of HL-60 promyelocyte differentiation by leukocyte-conditioned medium but not by phorbol ester. *Cancer Res* 1984; 44:4281-4.
46. Sabbath K, Ball ED, Schlossman SF, **Griffin JD**. Heterogeneity of clonogenic cells in acute myeloblastic leukemia assessed by surface marker analysis. *J Clin Invest* 1985; 75:746-53.
47. Cannistra SA, Daley JF, Larcom P, **Griffin JD**. Expression of Ia antigens on myeloid progenitor cells in chronic myeloid leukemia: Direct analysis using partially purified colony-forming cells. *Blood* 1985; 65:414-22.
48. **Griffin JD**, Sabbath KD, Herrmann F, Larcom P, Nichols K, Kornacki M, Levine H, Cannistra SA. Differential expression of HLA-DR antigens in subsets of human CFU-GM. *Blood* 1985; 66:788-795.
49. Koizumi S, Curt GA, Fine RL, **Griffin JD**, Chabner BA. Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. *J Clin Invest* 1985; 75:1008-1014.
50. Canellos GP, **Griffin JD**. Chronic granulocytic leukemia: The heterogeneity of stem cell differentiation within a single disease entity. *Semin Oncol* 1985; 12:281-8.
51. Boyd AW and **Griffin JD**. Detection of nonrandom clustering of colonies in agar culture. *Exp Hematol* 1985; 13(7):696-700.
52. Scholnick T, Beveridge RP, **Griffin JD**. Acute undifferentiated leukemia: Induction of partial differentiation by phorbol ester. *Leuk Res* 1985; 9:11-17.
53. Spriggs D, **Griffin JD**, Wisch J, Kufe D. Clinical pharmacology of low dose Ara-C. *Blood* 1985; 65:1087-1089.

54. Hercend T, **Griffin JD**, Bensussan A, Brennan A, Schmidt R, Edson MA, Daley JF, Schlossman SF, Ritz J. Generation of monoclonal antibodies to human NK clones: Characterization of two NK associated antigens, NKH1A (200-220Kd) and NKH2 (60Kd), expressed on subsets of large granular lymphocytes. *J Clin Invest* 1985; 75:932-43.
55. Bernal SD, Mabry M, Stahel RA, **Griffin JD**, Speak JA. Selective cytotoxicity of SM1 monoclonal antibody towards small cell carcinoma of the lung. *Cancer Res* 1985; 45:1026-32.
56. **Griffin JD**, Spriggs D, Wisch JS, Kufe DW. Treatment of preleukemic syndromes with continuous intravenous infusion of low dose cytarabine. *J Clin Oncol* 1985; 3:982-991.
57. **Griffin JD**, Maguire ME, Mayer RJ. Amsacrine in refractory acute leukemia. *Cancer Treat Reports* 1985; 787-789.
58. Biondi A, Roach JA, **Griffin JD**, Todd RF. Mb1, a plasma membrane antigen selectively expressed by U937 cells. *Blood* 1985; 66:135-42.
59. Mabry M, Speak JA, **Griffin JD**, Stahel RA, Bernal SD. The use of SM1 monoclonal antibody and human complement in selective killing of small cell carcinoma of the lung. *J Clin Invest* 1985; 75:1690-5.
60. Matutes E, Rodriguez B, Polli N, DeCastro JT, Parreira A, Andrews C, **Griffin JD**, Tindle RW, Catovsky D: Characterization of myeloid leukemias with monoclonal antibodies 3C5 and MY9. *Hematol Oncol* 1985; 3:179-186.
61. **Griffin JD**, Larcom P, Kufe DW. TPA induces differentiation of purified human myeloblasts in the absence of proliferation. *Exp Hematol* 1985; 13:1205-32.
62. Koizumi S, Fine RL, Curt GA, **Griffin JD**, Chabner BA. Enrichment of myeloid progenitor cells from normal human bone marrow using an immune-rosette technique. *Exp Hematol* 1985; 13:560-565.
63. Watanabe T, Mitchell T, Sariban E, Sabbath K, **Griffin JD**, Kufe D. Effects of 1-beta-arabinosylcytosine and phorbol ester on differentiation of human K562 erythroleukemia cells. *Mol Pharmacol* 1985; 27:683-8.
64. Avnstrom S, Plesner T, Ralfkier E, Claesson M, **Griffin JD**, Nissen NI. Expression of an antigen defined by a monoclonal antibody (SA-1) on normal and malignant cells. *Scand J Haematol* 1985; 35:408-17.
65. Herrmann F, Cannistra SA, Levine H, **Griffin JD**. Expression of interleukin 2 receptors and binding of interleukin 2 by gamma-interferon induced leukemic and normal monocytic cells. *J Exp Med* 1985; 162:1111-1116.
66. Cannistra SA, Herrmann F, Davis R, Nichols K, **Griffin JD**. The relationship between HLA-DR expression by normal myeloid progenitor cells and institution of colony growth by prostaglandin E (PGE): Implications for PGE resistance in chronic myeloid leukemia. *J Clin Invest* 1985; 77:13-20.

67. **Griffin JD**, Sabbath KD, Herrmann F, Larcoma P, Nichols K, Kornacki M, Levine H, Cannistra SA. Differential expression of HLA-DR antigens in subsets of human CFU-GM. *Blood* 1985; 66:788-795.
68. Sabbath KD, **Griffin JD**. Clonogenic cells in acute myeloblastic leukaemia. *Scand J Haematol* 1985; 35:251-256.
69. Picus J, Holley K, Aldrich WR, **Griffin JD**, Letvin NL. A naturally occurring bone marrow-chimeric primate. II. Environment dictates restriction on cytolytic T lymphocyte-Target cell interactions. *J Exp Med* 1985; 162:2035-2052.
70. Hokland P, Kerndrup G, **Griffin JD**, Ellegaard J. Analysis of leukocyte differentiation antigens in blood and bone marrow from preleukemia (refractory anemia) patients using monoclonal antibodies. *Blood* 1986; 67:898-902.
71. Herrmann F, Cannistra SA, **Griffin JD**. T cell-monocyte interactions in the production of humoral factors regulating human granulopoiesis in vitro. *J Immunol* 1986; 136:2856-61.
72. Herrmann F, Cannistra SA, **Griffin JD**. T cell-monocyte interactions in the production of humoral factors regulating human granulopoiesis in vitro. *J Immunol* 1986; 136:2856-61.
73. **Griffin JD**, Young D, Herrmann F, Wiper D, Wagner K, Sabbath KD. Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. *Blood* 1986; 67:1448-53.
74. **Griffin JD** and Lowenberg B: Clonogenic cells in acute myeloblastic leukemia. *Blood* 1986; 68:1185-95.
75. **Griffin JD**, David R, Nelson D, Davey FR, Mayer RJ, Schiffer C, McIntyre OR, Bloomfield CD. Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. *Blood* 1986; 68:1232-41.
76. Gee CE, **Griffin JD**, Sastre L, Miller LJ, Springer TA, Piwnica-Worms H, Roberts TM. Differentiation of myeloid cells is accompanied by increased levels of pp60^{c-src} protein and kinase activity. *Proc Natl Acad Sci USA (USA)* 1986; 83:5131-5.
77. Arnaout MA, Styrt B, **Griffin JD**, Todd RF III, Klempner MS, Dana N. Mapping of a phagocyte surface glycoprotein (Mo1) using monoclonal antibodies: Identification of two functional domains; one involved in C3bi binding and another in granulocyte adhesion. *J Immunol* 1986; 137:3259-63.
78. Young DC, **Griffin JD**. Autocrine secretion of GM-CSF in acute myeloblastic leukemia. *Blood* 1986; 68:1178-81.
79. Greenberger JS, Fitzgerald TJ, Rothstein L, Pierce J, Sakakeeny MA, Weichselbaum RR, Naparstek E, Newburger P, **Griffin JD**, Bast R Jr., et al.

- Long-term culture of human granulocytes and granulocyte progenitor cells. *Prog Clin Biol Res* 1986; 211:159-85.
80. Herrmann F, Schmidt RE, Ritz J, **Griffin JD**. Regulation of human hematopoiesis by natural killer cells: Analysis at a clonal level. *Blood* 1987; 69:246-54.
81. Young DC, Wagner K, **Griffin JD**. Constitutive expression of the GM-CSF gene in acute myeloblastic leukemia. *J Clin Invest* 1987; 79:100-6.
82. Band H, Corredor V, Lustgarten BS, Huebner K, **Griffin JD**, Kufe DW, Yunis EJ. Southern blot analysis of BII cell line - a putative variant of HL-60. *Leukemia* 1987; 1:142-5.
83. Rambaldi A, Young DC, **Griffin JD**. Expression of the M-CSF gene by human monocytes. *Blood* 1987; 69:1409-1413.
84. Sullivan R, Melnick DA, Meshulam T, Simons ER, Lazzari KG, Proto P, **Griffin JD**. The effects of phorbol myristate acetate and chemotactic peptide on transmembrane potentials and cytosolic free calcium in mature granulocytes are absent in normal granulocyte precursors and develop as the cells mature. *J Biol Chem* 1987; 262:1274-81.
85. Sariban E, Mitchell T, **Griffin JD**, Kufe D. Delayed expression of the c-fos and c-fms proto-oncogenes during interferon gamma induced monocytic differentiation. *J Immunol* 1987; 138:1954-58.
86. Rambaldi A, Young DC, Herrmann F, Cannistra SA, **Griffin JD**. Gamma-interferon induces expression of the IL-2 receptor gene in human monocytes. *Eur J Immunol* 1987; 17:153-6.
87. Sobol RE, Mick R, Roystan I, Davey FR, Ellison RR, Newman R, Cuttner J, **Griffin JD**, Collins H, Nelson DA, Bloomfield CD. Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. *New Engl J Med* 1987; 316:1111-7.
88. Cannistra SA, Rambaldi A, Spriggs DR, Herrmann F, Kufe D, **Griffin JD**. Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes. *J Clin Invest* 1987; 79:1720-8.
89. Vellenga E, Young DC, Wagner K, Wiper D, Ostapovicz D, **Griffin JD**. The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. *Blood* 1987; 69:1771-6.
90. Boyd AW, Tedder TF, **Griffin JD**, Freedman AS, Fisher DC, Daley J, Nadler LM. Pre-exposure of resting B cells to interferon-gamma enhances their proliferation response to subsequent activation signals. *Cellular Immunol.* 1987; 106:355-65.
91. Sullivan R, **Griffin JD**, Malech HL. Acquisition of formyl peptide receptors during normal human myeloid differentiation. *Blood* 1987; 70:1222-4.

92. Vellenga E, Ostapovicz D, O'Rourke B, and **Griffin JD**. The effects of recombinant IL-3, GM-CSF and G-CSF on proliferation of leukemic clonogenic cells in short-term and long-term cultures. *Leukemia* 1987; 1:584-89.
93. **Griffin JD**, Rambaldi A, Vellenga E, Young DC, Ostapovicz D, and Cannistra SA. Constitutive secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. *Blood* 1987; 70:1218-21.
94. Sullivan R, **Griffin JD**, Simons ER, Schafer AI, Meshulam T, Fredette JP, Maas AK, Gadenne AS, Leavitt JL, Melnick DA. Effects of recombinant human granulocyte and macrophage colony-stimulating factors on signal transduction pathways in human granulocytes. *J Immunol* 1987; 139:3422-30.
95. **Griffin JD**. Growth factors required for proliferation of clonogenic cells in acute myeloblastic leukemia (AML). *Haematologica* 1987; 72:85-8.
96. Herrmann F, Oster W, Lindemann A, Ganser A, Dorken B, Knapp W, **Griffin JD**, Mertelsmann R. Leukemic colony-forming cells in acute myeloblastic leukemia: Maturation hierarchy and growth conditions. *Hamatol Bluttransfus* 1987; 31:185-90.
97. Cannistra SA, Vellenga E, Rambaldi A, **Griffin JD**. Human interleukin-3 and granulocyte-monocyte colony stimulating factor enhance monocyte cytotoxicity by modulating expression of the tumor necrosis factor gene. *Blood* 1988; 71:672-6.
98. Vellenga E, Rambaldi A, Ernst T, Ostapovicz D, **Griffin JD**. Independent regulation of the M-CSF and G-CSF genes in human monocytes. *Blood* 1988; 71:1529-32.
99. Rambaldi A, Wakamiya N, Vellenga E, Horiguchi J, Warren MK, Kufe DW, **Griffin JD**. In vitro expression of the macrophage colony stimulating factor and c-fms genes in human acute myeloblastic leukemia cells. *J Clin Invest* 1988; 81:1030-35.
100. Young DC, Demetri GD, Ernst TJ, Cannistra SA, **Griffin JD**. In vitro expression of colony stimulating factor genes by human acute myeloblastic leukemia cells. *Exp Hematol* 1988; 16:378-82.
101. Simpson PJ, Todd RF, Fautone JC, Mickelson JK, **Griffin JD**, Lucchesi B. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. *J Clin Invest* 1988; 81:624-9.
102. Socinski MA, Cannistra SA, Sullivan R, Elias A, Antman K, Schnipper L, **Griffin JD**. Human granulocyte-macrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on granulocytes in vivo. *Blood* 1988; 72:691-7.

103. Keinanen M, **Griffin JD**, Bloomfield CD, Machnicki J, de la Chapelle A. Clonal chromosome abnormalities directly demonstrate multiple cell lineage involvement in acute myeloid leukemia. *New Engl J Med* 1988; 318:1153-8.
104. Ernst TJ, Rosenthal DS, **Griffin JD**, Canellos GP. Treatment of the blastic phase of chronic myelogenous leukemia with high dose cytosine arabinoside. *Am J Clin Oncol* 1988; 11:623-6.
105. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, **Griffin JD**. Granulocyte-macrophage colony-stimulating factor expands the circulating hematopoietic progenitor cell compartment in humans. *Lancet* 1988; 1:1194-8.
106. Cannistra SA, Groshek P, **Griffin JD**. Monocytes enhance gamma-interferon induced inhibition of myeloid progenitor cell growth through secretion of tumor necrosis factor. *Exp Hematol* 1988; 16:865-70.
107. Wang JM, **Griffin JD**, Rambaldi A, Mantovani A. Induction of monocyte migration by recombinant macrophage-colony stimulating factor. *J. Immunol.* 1988; 141:575-9.
108. Antman KS, **Griffin JD**, Elias A, Socinski MA, Ryan L, Cannistra SA, Oette D, Whitley M, Frei E, Schnipper LE. The effect of recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) on chemotherapy-induced myelosuppression. *New Engl J Med* 1988; 319:593-8.
109. Sullivan R, **Griffin JD**, Wright J, Melnick DA, Leavitt JL, Fredette JP, Horne JH Jr, Lyman CA, Lazarri KG, Simons ER. Effects of recombinant human granulocyte-macrophage colony-stimulating factor on intracellular pH in mature granulocytes. *Blood* 1988; 72:1665-73.
110. Herrmann F, **Griffin JD**, Sabbath KD, Oster W, Wernet P, Mertelsmann R. Identification and purification of human erythroid progenitor cells by monoclonal antibody to the transferrin receptor (TU67). *Blut* 1988; 56:179-83.
111. Herrmann F, Cannistra SA, Lindemann A, Blohm D, Rambaldi A, Mertelsmann R, **Griffin JD**. 1988. Functional consequences of monocyte interleukin-2 receptor expression: Induction of interleukin-1-beta secretion by gamma interferon and interleukin-2. *J. Immunol.* 1989; 142:139-143.
112. Ernst TJ, Ritchie AR, Demetri GD, **Griffin JD**. Regulation of granulocyte and monocyte-colony stimulating factor mRNA levels in human blood monocytes is mediated primarily at a post-transcriptional level. *J Biol Chem* 1989; 264:5700-5703.
113. Cannistra SA, Groshek P, **Griffin JD**. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. *Leukemia* 1989; 3:328-33.

114. Rosmarin AG, Weil SC, Rosner GL, **Griffin JD**, Arnout MA, Tenen DG. Differential expression of CD11b/CD18 (Mo1) and myeloperoxidase genes during myeloid differentiation. *Blood* 1989; 73:131-6.
115. Demetri GD, Zenzie BW, Rheinwald JG, **Griffin JD**. Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cell lines in vitro. *Blood* 1989; 74:940-6.
116. Sullivan R, Fredette JP, **Griffin JD**, Leavitt JL, Simons ER, Melnick DA. An elevation in the concentration of free cytosolic calcium is sufficient to activate the oxidative burst of granulocytes primed with recombinant human granulocyte-macrophage colony-stimulating factor. *J Biol Chem* 1989; 264:6302-6309.
117. Davey FR, Davis RB, MacCallum JM, Nelson DA, Mayer RJ, Ball ED, **Griffin JD**, Schiffer, Bloomfield CD. Morphologic and cytochemical characteristics of acute promyelocytic leukemia. *Am J Hematol* 1989; 30:221-27.
118. Ball ED, McDermott J, **Griffin JD**, Davey FR, Davis R, Bloomfield CD. Expression of the three myeloid cell-associated immunoglobulin G Fc receptors defined by murine monoclonal antibodies on normal bone marrow and acute leukemia cells. *Blood* 1989; 73:1951-6.
119. Sullivan R, Fredette JP, Socinski M, Elias A, Antman K, Schnipper L, **Griffin JD**. Enhancement of superoxide anion release by granulocytes harvested from patients receiving granulocyte-macrophage colony-stimulating factor. *Br J Haematol* 1989; 71:475-9.
120. Ernst RJ, Richie AR, O'Rourke R, **Griffin JD**. Colony-stimulating factor gene expression in human acute myeloblastic leukemia is post-transcriptionally regulated. *Leukemia* 1989; 3:620-5.
121. Sullivan R, Fredette JP, Leavitt JL, Gadenne A-S, **Griffin JD**, Simons ER. Effects of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF_{rh}) on transmembrane electrical potentials in granulocytes: Relationship between enhancement of ligand-mediated depolarization and augmentation of superoxide anion (O₂⁻) production. *J Cell Physiol* 1989; 139:361-9.
122. Chang HC, Hsu F, Freeman G, **Griffin JD**, Reinherz EL. Cloning and expression of a g-interferon inducible gene in monocytes: A new member of a cytokine gene family. *Int Immunol* 1989; 1:388-97.
123. DeCaprio JA, Ludlow JW, Lynch D, Furukawa UY, Griffin J, Piwnicka-Worms H, Huang C, Livingston DM. The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. *Cell* 1989; 58:1085-95.
124. Holland CA, Rothstein L, Sakakeeny MA, Anklesaria P, **Griffin JD**, Harigaya K, Newburger P, Greenberger JS. Differential expression of the neomycin resistance gene transferred by a retroviral vector to hematopoietic and stromal cells in human continuous bone marrow cultures. *Acta Haematologica* 1989; 82:136-43.

125. Demetri GD, **Griffin JD**. Hemapoietins and leukemia. Heme-Onc Clinics of N America 1989; 3:535-553.
126. Cannistra SA, Groshek P, Garlick R, Miller J, **Griffin JD**. Regulation of surface expression of the granulocyte-macrophage colony-stimulating receptor in normal human myeloid cells. Proc Natl Acad Sci (USA) 1990; 87:93-7.
127. Bauer KA, Conway EM, Bach R, Konigsberg WH, **Griffin JD**, Demetri G. Tissue factor gene expression in acute myeloblastic leukemia. Throm Res 1989; 56:423-430.
128. Keinanen M, Bloomfield CD, Machnicki J, **Griffin JD**, De la Chapelle A. Human bone marrow cytogenetics: Growth factors stimulate metaphases for specific lineages. Leukemia 1989; 3:405-12.
129. Nakamura M, Merchav S, Ernst TJ, Demetri GD, Furukawa Y, Anderson K, Freedman AS, Freeman G, **Griffin JD**. Expression of a novel 3.5 kb macrophage colony-stimulating factor transcript in human myeloma cells. J Immunol 1989; 143:3543-47.
130. **Griffin JD**, Cannistra SA, Sullivan R, Demetri GD, Ernst TJ, Kanakura Y. The biology of GM-CSF: Regulation of production and interaction with its receptor. Int J of Cell Cloning 1990; 8:35-45.
131. Cannistra SA, Koenigsmann M, DiCarlo J, Groshek P, **Griffin JD**. Differentiation-associated expression of two functionally distinct classes of GM-CSF receptors by human myeloid cells. J Biol Chem 1990; 265:12656-12663.
132. Furukawa Y, DeCaprio JA, Freedman A, Kanakura Y, Nakamura M, Ernst TJ, Livingston DM, **Griffin JD**. Expression and state of phosphorylation of the retinoblastoma and susceptibility gene product in cycling and non-cycling human hematopoietic cells. Proc Natl Acad Sci (USA) 1990; 87:2770-2774.
133. Ord DC, Ernst TJ, Zhou LJ, Rambaldi A, Sertini O, **Griffin JD**, Tedder TF. Structure of the gene encoding the human leukocyte adhesion molecule-1 of lymphocytes and neutrophils. J Biol Chem 1990; 14:7760-7767.
134. Nakamura M, Kanakura Y, Furukawa Y, Ernst TJ, **Griffin JD**. Demonstration of interleukin 1b transcripts in acute myeloblastic leukemia cells by *in situ* hybridization. Leukemia 1990; 4:466-70.
135. Kanakura Y, Druker B, Cannistra SA, Furukawa Y, Torimoto Y, **Griffin JD**. Signal transduction of the human GM-CSF and IL-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins. Blood 1990; 76:706-715.
136. **Griffin JD**, Sertini O, Ernst TJ, Belvin MP, Levine HB, Kanakura Y, Tedder TF. Granulocyte-macrophage colony-stimulating factor and other cytokines regulate surface expression of the leukocyte adhesion molecule-1 on human neutrophils, monocytes, and their precursors. J Immunol 1990; 145:576-584..

137. Sharkis SJ, Jones RJ, Bellis ML, Demetri GD, **Griffin JD**, Civin C, May WS. The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors. *Blood* 1990; 76:716-20.
138. Demetri GD, Rheinwald G, Ernst TJ, **Griffin JD**. Expression of *ras* oncogenes in cultured human cells alter the transcriptional and post-transcriptional regulation of cytokine genes. *J Clin Invest* 1990; 86:1261-1269.
139. Furukawa Y, Piwnica-Worms H, Ernst TJ, Kanakura Y, **Griffin JD**. Cdc2 gene expression at the G1 to S transition in human T lymphocytes. *Science* 1990; 250:805-808.
140. Kanakura Y, Druker B, DiCarlo J, Cannistra SA, **Griffin JD**. Phorbol 12-myristate 13-acetate inhibits granulocyte-macrophage colony stimulating factor-induced protein tyrosine phosphorylation in a human factor-dependent hematopoietic cell line. *J Biol Chem* 1991; 266:490-5.
141. Spertini O, Kansas GS, Munro JM, **Griffin JD**, Tedder TF. Regulation of leukocyte migration by activation of the leukocyte adhesion molecule-1 (TQ1, LEU-8). *Nature* 1991; 349:691-694.
142. Kanakura Y, Druker B, Wood KW, Mamon HJ, Okuda K, Roberts TM, **Griffin JD**. GM-CSF and IL-3 induce rapid phosphorylation and activation of the proto-oncogene Raf-1 in human factor-dependent myeloid cell line. *Blood* 1991; 77:243-248.
143. Kanakura Y, Cannistra SA, Brown CB, Nakamura M, Seelig GF, Prosser WW, Hawkins JC, Kaushansky K, **Griffin JD**. Identification of functionally distinct domains of human granulocyte-macrophage colony-stimulating factor using monoclonal antibodies. *Blood* 1991; 77:1033-1043.
144. Roy DC, **Griffin JD**, Belvin M, Blattler WA, Lambert JM, Ritz J. Anti-My9-blocked ricin: An immunotoxin for selective targeting of acute myeloid leukemia cells. *Blood* 1991; 77:2404-2412.
145. Spertini O, Freedman AS, Belvin M, **Griffin JD**. Regulation of leukocyte adhesion molecule-1 (TQ1, Leu-8) expression and shedding by normal and malignant cells. *Leukemia* 1991; 5:300-308.
146. Furukawa Y, DeCaprio JA, Belvin M, **Griffin JD**. Heterogenous expression of the product of the retinoblastoma susceptibility gene in primary human leukemia cells. *Oncogene* 1991; 6:1343-1346.
147. Shipp MA, Stefano GB, Switzer SN, **Griffin JD**, Reinherz EL. CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation. *Blood* 1991; 78:1834-1841.
148. Cannistra SA, DiCarlo J, Groshek P, Kanakura Y, Berg D, Mayer RJ, **Griffin JD**. Simultaneous administration of granulocyte-macrophage colony stimulating

- factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. *Leukemia*. 1991; 5:230-238.
149. Ball ED, Davis RB, **Griffin JD**, Mayer RJ, Davey FR, Arthur DC, Wurster-Hill D, Noll W, Elghetany T, Allen SL, Rai K, Lee EJ, Schiffer CA, Bloomfield CD. Prognostic value of lymphocyte markers in acute myeloid leukemia. *Blood* 1991; 77:2242-2250.
 150. Okuda K, Druker B, Kanakura Y, Koenigsmann M, **Griffin JD**. Internalization of the granulocyte-macrophage colony stimulating factor receptor is not required for induction of protein tyrosine phosphorylation in human myeloid cells. *Blood* 1991; 78:1928-1935.
 151. DeCaprio JA, Furukawa Y, Ajchenbaum F, **Griffin JD**, Livingston DM. The retinoblastoma gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. *Proc Natl Acad Sci (USA)* 1992;89:1795-1798.
 152. Ishida Y, Furukawa Y, DeCaprio JA, Saito M, **Griffin JD**. Treatment of myeloid leukemic cells with the phosphatase inhibitor okadaic acid induces cell cycle arrest at either G1/S or G2/M depending on dose. *J Cell Physiol* 1992; 150:484-492.
 153. Spertini O, Luscinskas W, Kansas GS, Munro JM, **Griffin JD**, Gimbrone MA, Tedder TF. Leukocyte adhesion molecule-1 (Lam-1, I-selectin) interacts with an inducible endothelial cell ligand to support leukocyte adhesion. *J Immunol* 1991; 147:2565-2573.
 154. Ikeda H, Kanakura Y, Tamaki T, Kuriu A, Kitayama H, Ishikawa J, Kanayama Y, Yonezawa T, Tarui S, **Griffin JD**. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. *Blood* 1991; 78:2962-2968.
 155. Okuda K, Sanghera J, Pelech SL, Kanakura Y, Hallek M, **Griffin JD**, Druker B. GM-CSF and steel factor induce rapid tyrosyl phosphorylation of p42 MAP kinase. *Blood* 1992;79:2880-2887.
 156. Koenigsmann M, **Griffin JD**, DiCarlo J, Cannistra SA. Myeloid and erythroid progenitor cells from normal bone marrow adhere to collagen type I. *Blood* 1992; 79:657-665.
 157. Druker B, Okuda K, Matulonis U, Salgia R, Roberts T, **Griffin JD**. Tyrosine phosphorylation of ras GAP and associated proteins in chronic myelogenous leukemia cell lines. *Blood* 1992; 79:2215-2220.
 158. Robertson M, Soiffer R, Freedman A, Rabinowe S, Anderson K, Ervin T, Murray C, Dear K, **Griffin JD**, Nadler L, Ritz J. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: Clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. *Blood* 1992; 79:2229-2236.
 159. Tamaki T, Kanakura Y, Kuriu A, Ikeda H, Mitsui H, Yagura H, Matsumura I, Druker B, **Griffin JD**, Kanayama Y. Surface immunoglobulin-mediated signal

transduction involves a rapid phosphorylation and activation of the proto-oncogene product Raf-1 in human B cells. *Cancer Res* 1992; 52:566-570.

160. Hallek M, Druker B, Lepisto E, Wood K, Ernst T, **Griffin JD**. Granulocyte-macrophage colony-stimulating factor and Steel factor induce phosphorylation of both unique and overlapping signal transduction intermediates in a human factor dependent hematopoietic cell line. *J Cell Physiol* 1992; 153: 176-186.
161. Petros W, Rabinowitz J, Stuart A, Gilbert C, Kanakura Y, **Griffin JD**, Peters W. Disposition of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving high-dose chemotherapy and autologous bone marrow support. *Blood* 1992; 80:1135-1140.
162. Gribben JG, Saporito L, Barber M, Blake KW, Edwards RM, **Griffin JD**, Freedman AS, Nadler LM. Bone marrows of non-Hodgkins's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. *Blood* 1992; 80:1083-1089.
163. Hallek M, Lepisto EM, Slattery K, **Griffin JD**, Ernst T. Interferon-gamma increases expression of the gene encoding the b-subunit of the GM-CSF receptor. *Blood* 1992; 80:1736-1742.
164. La Russa VF, **Griffin JD**, Kessler SW, Cutting MA, Knight RD, Blattler WA, Lambert JM, Wright DG. Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures. *Exp Hematol* 1992; 20:442-8.
165. Ajchenbaum FA, Ando K, DeCaprio J, **Griffin JD**. Independent regulation of human D-type cyclins during the G1 phase in primary human T-lymphocytes. *J Biol Chem* 1993;268:4113-9.
166. Stone RM, Spriggs DR, Arthur KA, Mayer RJ, **Griffin JD**, Kufe DW. Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplastic syndromes. *Am J Clin Oncol* 1993; 16:159-163.
167. Eder M, **Griffin JD**, Ernst TJ. The human GM-CSF receptor is capable of initiating signal transduction in NIH 3T3 cells. *EMBO J* 1993 12:1647-1656.
168. Robertson M, Tanatravahi R, **Griffin JD**, Canellos G, Cannistra S. Hematologic Remission and cytogenetic improvement after treatment of chronic myelogenous leukemia with continuous infusion of low-dose cytarabine. *Am J Hematol*, in press, 1993.
169. Park S, Schalling M, Bernard A, Maheswaran S, Shipley G, Roberts D, Fletcher J, Shipman R, Rheinwald J, Demetri G, **Griffin J**, Minden M, Housman D, Haber D. The Wilms tumor gene WT1 is expressed in mesoderm-derived tissues and mutated in mesothelioma. *Nature Genetics* 4:415-420, 1993.

170. Ando K, Ajchenbaum F, **Griffin JD**. Regulation of G1/S transition by cyclins D2 and D3 in hematopoietic cells. *Proc Natl Acad Sci (USA)* 1993; 90:9571-9575.
171. Matulonis U, Salgia R, Okuda K, Druker B, **Griffin JD**. IL-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. *Exp Hematol* 1993; 21:1460-1466.
172. Carlesso N, **Griffin JD**, Druker BJ. Use of a temperature-sensitive mutant to define the biological effects of the p210bcr/abl tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. *Oncogene* 1994; 9:149-156.
173. Matsuguchi T, Salgia R, Hallek M, Eder M, Druker, Ernst T, **Griffin JD**. Shc phosphorylation in myeloid cells is regulated by GM-CSF, IL-3, and Steel Factor and is constitutively increased by p210BCR/ABL. *J Biol Chem* 1994; 269:5016-5021..
175. Ernst TJ, Slattery KE, **Griffin JD**. p210BCR/ABL and p160v-ABL Induce an Increase in the Tyrosine Phosphorylation of p93c-FES. *J Biol Chem* 1994; 269:5764-69.
176. Hallek M, Ando K, Eder M, Slattery K, Ajchenbaum-Cymbalista, **Griffin JD**. Signal transduction of Steel factor and granulocyte-macrophage colony stimulating factor: Differential regulation of transcription factor and G1 cyclin gene expression. *Leukemia* 1994; 8:740-48.
177. Druker B, Okuda K, Neumann M, Franza BR, **Griffin JD**. Rel is rapidly tyrosine phosphorylated following granulocyte colony-stimulating factor treatment of human neutrophils. | *J Biol Chem* 1994; 269:5387-90.
178. Quelle FW, Witthuhn BA, Inhorn R, Ernst TJ, Miyajima A, **Griffin JD**, Ihle JN. JAK2 associates with the Bc chain of the receptor for GM-CSF and its activation requires the membrane proximal region. *Mol Cell Biol* 1994;14:4335-4341.
179. Okuda K, Ernst TJ, **Griffin JD**. Inhibition of p21ras activation blocks proliferation but not differentiation of IL-3-dependent myeloid cells. *J Biol Chem* 1994; 269:24602-24607.
180. Oda T, Heaney C, Hagopian, JR, Okuda K, **Griffin JD**, Druker BJ. CRKL is the major tyrosine phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. *J Biol Chem* 1994; 269:22925-8
181. Matulonis U, Dosiou C, Lamont C, Freeman GJ, Mauch P, Nadler LM, **Griffin JD**. Role of B7-1 In mediating an immune response to myeloid leukemia cells. *Blood* 1995; 85:2507-2515.
182. Matulonis UA., **Griffin JD**, Canellos GP. Autologous peripheral stem cell transplantation of the blastic phase of chronic myeloid leukemia following sequential high-dose cytosine arabinoside and melphalan. *Am J Hematol* 1994; 45:283-7.

183. Eder M, Ernst TJ, Ganzer A, Jubinsky PT, Inhorn R, Hoelzer D, **Griffin JD**. A low affinity chimeric human a/b-granulocyte-macrophage colony-stimulating factor receptor induces ligand-dependent proliferation in a murine cell line. *J Biol Chem* 1994; 269:30173-30180.
184. Ando K, **Griffin JD**. Cdk4 Integrates Growth Stimulatory and Inhibitory Signals During G1 Phase of Hematopoietic Cells. *Oncogene* 1995; 10:751-5
185. Salgia R, Li J-L, Lo SH, Brunkhorst B, Kansas GS, Sobhany ES, Sun Y, Pisick E, Hallek M, Ernst T, Tantravahi R, Chen LB, and **Griffin JD**. Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by p210bcr/abl. *J Biol Chem* 1995; 270:5039-5047
186. Davey FR, Abraham N, Brunetto VL, MacCallum JM, Nelson DA, Ball ED, **Griffin JD**, Baer MR, Wurster-Hill D, Mayer RJ, Schiffer CJ, Bloomfield C. Morphologic characteristics of erythroleukemia (acute myeloid leukemia; FAB M6): A CALGB study. *Am J Hematology* 49:29-38, 1995.
187. Salgia R, Brunkhorst B, Pisick E, Li J-L, Lo SH, Chen LB, **Griffin JD**. Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL, *Oncogene* 1995; 11:1149-55.
188. Avalos BR, Broudy VC, Ceselski SK, Druker BJ, **Griffin JD**, Hammond WP. Abnormal response to granulocyte colony-stimulating factor (G-CSF) in canine cyclic hematopoiesis is not caused by altered by G-CSF receptor expression. *Blood* 1994; 84:789-794.
189. Inhorn RC, Carlesso N, Durstin M, Frank DA, **Griffin JD**. Identification of a viability domain in the granulocyte-macrophage colony-stimulating factor receptor b-chain involving tyrosine-750 *Proc Natl Acad Sci* 1995, 92:8665-9
190. Drachman JG, **Griffin JD**, Kaushansky K. The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl. *J Biol Chem* 1995 10;270:4979-82
191. Oda T, Tamura S, Matsuguchi T, **Griffin JD**, Druker BJ. The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line. *Leukemia* 1995 9:295-301
191. Matsuguchi T, Inhorn RC, Carlesso N, Xu G, Druker B, **Griffin JD**. Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM-CSF, IL-3 and Steel factor and is constitutively increased by p210BCR/ABL. *EMBO Journal* 1995 14:257-65
192. Boussiotis VA, Freeman GJ, **Griffin JD**, Gray GS, Gribben JG, Nadler LM. CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy. *J Exp Med* 1994 ;180:1665-73
193. Sattler M, Durstin M, Frank DA, Okuda K, Kaushansky K, Salgia R, **Griffin JD**. The thrombopoietin (TPO) receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. *Exp Hematol* 1995; 23:1040-1048

194. Salgia R, Uemura N, Okuda K, Li J-L, Pisick E, Sattler M, de Jong R, Druker B, Chen LB, Groffen J, and **Griffin JD**. CRKL is tyrosine phosphorylated and constitutively links p210BCR/ABL to paxillin in CML cells. *J Biol Chem* 1995; 270: 29145-50.
195. Carlesso N, Frank DA and **Griffin JD**. Constitutive Phosphorylation of STAT Proteins in Hematopoietic Cells Transformed by Bcr/Abl. *J Exp. Med* 1996, 183:811-20
196. Sattler M, Salgia R, Pisick E, Li J-L, **Griffin JD**. p210^{BCR/ABL} induces formation of complexes containing focal adhesion proteins and the protooncogene product p120^{c-CBL}. *Exp Hematol* 1996; 24:310-3
197. Durstin M, Inhorn RC, **Griffin JD**. Tyrosine phosphorylation of Shc is not required for proliferation or viability signaling by GM-CSF. *J. Immunol* 1996; 157:534-540.
198. Okuda K, Gollub T, Gilliland G, **Griffin JD**. p210Bcr/Abl, p190Bcr/Abl, and Tel/Abl activate similar signal transduction pathways in hematopoietic cell lines. *Oncogene*, 1996; 13:1147-52
199. Uemura N, Salgia S, Li J-L, Pisick E, Sattler M, **Griffin JD**. Interaction of the adapter protein Crkl with cellular proteins in normal and Bcr/Abl-transformed cells. *Leukemia* 1997 11:376-85
200. Matulonis U, Dosiou C, Freeman G, Lamont C, Mauch P, Nadler LM, **Griffin JD**. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. *J Immunol* 1996, 156:1126-31, 1996.
201. Manie SN, Sattler M, Astier A, Phifer JS, Druker BJ, Morimoto C, Salgia R, **Griffin JD**, and Freedman AS. Tyrosine phosphorylation of the product of the c-cbl protooncogenesis induced after integrin stimulation. *Exp Hematol* 1997; 25(1):45-50.
202. Sattler M, Salgia R, Okuda K, Uemura N, Durstin M, Pisick E, Xu G, Li J-L, Prasad KY, **Griffin JD**. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. *Oncogene* 1996, 12:839-46.
203. Salgia R, Pisick E, Sattler M, Li J-L, Uemura N, Wong W-K, Hirai H, Chen LB, and **Griffin JD**. p130^{Cas} Binds CRKL in BCR/ABL Expressing Cells. *J Biol Chem* 1996, 271:25198-25203.
204. Salgia R, Avraham S, Pisick E, Li J-L, Raja S., Greenfield A, Sattler M, Avraham H, and **Griffin JD**. The Related Adhesion Focal Tyrosine Kinase, RAFTK, Forms a Complex with Paxillin in Hematopoietic Cells. *J. Biol Chem* 1996; 271: 31222-31226.

205. Salgia R, Sattler M, Pisick E, Li JL, **Griffin JD**. P210 BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl. *Exp Hematol* 1996; 24:310-3
206. Hallek M, Danheuser-Riedel S, Herbst R, Warmuth M, Winkler A, Kolb H-J, Druker B, **Griffin JD**, Emmerich B, Ullrich A. Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. *Brit J Haematol* 1996; 94: 5-16
207. Bazzoni G, Carlesso N, **Griffin JD**, Hemler ME. Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. *J Clin Invest* 1996; 98:521-8
208. Sattler M, Salgia R, Durstin MA, Prasad KV, and **Griffin JD**. Thrombopoietin induces activation of the phosphatidylinositol-3' kinase pathway and formation of a complex containing p85PI3K and the protooncoprotein p120CBL. *J Cell Physiol*, 1997, 171:28-33.
209. Sattler M, Shrikhande G, Verma S, Pisick E, Kanteti V.S. PrasadΔ, Salgia R, **Griffin JD**. Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, PI3K, and p120CBL. *J Biol Chem* 1997; 272: 10248-53.
210. Xia K, Mukhopadhyay NK, Inhorn RC, Barber DL, Rose PE, Lee RS, Narhimhan RP, D'Andrea AD, **Griffin JD**, Roberts TM. The cytokine activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner. *Proc Natl Acad Sci* 93:11681-11686, 1996.
211. Manie SN, Beck AR, Astier A, Law SF, Canty T, Hirai H, Druker BJ, Avraham H, Haghayeghi N. Sattler M, Salgia R, **Griffin JD**, Golemis EA, Freedman AS. Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells. *J Biol Chem* 1997; 272:4230-6
212. Salgia R, Li J-L, Ewaniuk DS, Pear W, Pisick E, Burky S, Ernst T, Sattler M, Chen LB, **Griffin JD**. BCR/ABL induces multiple abnormalities of cytoskeletal function. *J Clin Invest* 1997; 100:46-57
213. Okuda K, Smith L, **Griffin JD**, Foster R. Signaling functions of the tyrosine residues in the bc chain of the GM-CSF Receptor. *Blood*, 90: 4759-66, 1997
214. Okuda K, D'Andrea AD, Van Etten RA, **Griffin JD**. A Chimeric Receptor/Oncogene Which Can Be Regulated By A Ligand In Vitro And In Vivo. *J Clin Invest*, 100:1708-15, 1997.
215. Gu H, **Griffin JD**, Neel BG. Characterization of two SHP-2-associated binding proteins and potential substrates in hematopoietic cells. *J Biol Chem* 272:16421-30, 1997.
216. Sattler M, Salgia R, Shrikhande G, Verma S, Uemura N, Law SF, Golemis EA, **Griffin JD**. Differential signaling after beta1 integrin ligation is mediated through

- binding of CRKL to p120(CBL) and p110(HEF1). *J Biol Chem* 272(22):14320-6, 1997
217. Sattler M, Salgia R, Shrikhande G, Verma S, Choi J-L, Rohrschneider L, **Griffin JD**. The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors. *Oncogene* 15:2379-84, 1997.
 218. Tong X, Salgia R, Li J-L, **Griffin JD**, Howley PM. The bovine papillomavirus E6 protein binds to the LD motif repeats of paxillin and blocks its interaction with vinculin and the focal adhesion kinase. *J Biol Chem* 272:33373-33376, 1997.
 219. Hallek M, Neumann C, Schaffer M, Danhauser-Riedl S, von Bubnoff N, de Vos G, Druker BJ, Yasukawa K, **Griffin JD**, Emmerich B. Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines. *Exp Hematol* 25:1367-77, 1997
 220. Okuda K, D'Andrea A, Van Etten RA, and **Griffin JD**. The C-Terminus Of C-Abl Is Required For Proliferation And Viability Signaling In A C-Abl/Epo Receptor Fusion Protein. *Blood* 92:3848-56, 1998.
 221. Zhao RC, McIvor RS, **Griffin JD**, Verfaillie CM. Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo. *Blood*. 90:4687-98, 1997
 222. Uemura N, Salgia R, Ewaniuk D, Little M-T, **Griffin JD**. Involvement of the adapter protein CRKL in Integrin mediated adhesion. *Oncogene*. 18:3343-53, 1999.
 223. Reed MF, Liu VF, Ladha MH, Ando K, Griffin, JD, Weaver DT, Ewen ME. Enforced CDK4 expression in a hematopoietic cell line confers resistance to the G1 arrest induced by ionizing radiation. *Oncogene* 1998 17: 2961-2971
 224. Sattler M, Verma S, and **Griffin JD**. Hematopoietic growth factors signal through the formation of reactive oxygen species. *Blood* 93:2928-35, 1999.
 225. Salgia R, Quackenbush E, Lin J, Souchkova N, Sattler M, Ewaniuk D, Kulcher KM, Daley GQ, Kraeft SK, von Andrian UH, Chen LB, Gutierrez-Ramos J-C, Pendergast A-M, **Griffin JD**. The Bcr/Abl oncogene alters the chemotactic response to SDF-1a. *Blood* 94:4233-46, 1999.
 226. Sattler M, Verma S, Byrnes C, **Griffin JD**. BCR/ABL directly inhibits expression of SHIP, an SH2 containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis. *Mol Cell Biol* 19:7473-80, 1999.
 227. Salgia R, Li JL, Ewaniuk DS, Wang YB, Sattler M, Chen WC, Richards W, Pisick E, Shapiro GI, Rollins BJ, Chen LB, **Griffin JD**, Sugarbaker D. Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. *Oncogene*. 18:67-77, 1999.

228. Weisberg E and **Griffin JD**. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. *Blood* 95:3498-505, 2000.
229. Uemura N and **Griffin JD**. The Adapter Protein CRKL Links p120CBL To C3G After Integrin Ligation And Enhances Cell Migration. *J Biol Chem* 274: 37525-32, 1999.
230. Sillaber C, Gesbert F, Frank DA, Sattler M, **Griffin JD**. STAT5 activation contributes to growth and viability in Bcr/Abl transformed cell lines. *Blood* 2000 95: 2118-2125
231. Wu L, Aster JC, Blacklow SC, Lake R, Artavanis-Tsakonas S, **Griffin JD**. MAML1, a human homologue of Drosophila Mastermind Gene, encodes a transcriptional coactivator for Notch receptors. *Nature Genetics* 26:484-9, 2000.
232. Ichinohasama R, Miura I, Takahashi N, Sugawara T, Tamate E, Endoh K, Endoh F, Naganuma H, DeCoteau JF, **Griffin JD**, Kadin ME, Ooya K. Ph-negative non-Hodgkin's lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: report of two cases and review of the literature. *Leukemia*. 14:169-82, 2000.
233. Thomas JW, Cooley MA, Broome JM, Salgia R, **Griffin JD**, Lombardo CR, Schaller MD. The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin. *J Biol Chem* 274:36684-92, 1999.
234. Sattler M, Shrikhande G, Verma S, Salgia S, and **Griffin JD**. BCR/ABL induces production of reactive oxygen species. *J Biol Chem* 275:24273-24278, 2000.
235. Gesbert F, **Griffin JD**. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. *Blood*. 2000; 96:2269-76
236. Sun Y, Zhang J, Kraeft SK, Auclair D, Chang MS, Liu Y, Sutherland R, Salgia R, **Griffin JD**, Ferland LH, Chen LB. Molecular cloning and characterization of human trabeculin-alpha, a giant protein defining a new family of actin-binding proteins. *J Biol Chem* 274:33522-30, 1999
237. Varnum-Finney B, Wu L, Yu M, Brashem-Stein C, Staats S, Flowers D, **Griffin JD**, Bernstein ID. Ligand immobilization is required for Notch activation and Notch mediated inhibition of C2 myoblast differentiation. *J Cell Sci*,113:4313-8, 2000.
238. Shen Y, Lyons P, Cooley M, Davidson D, Veillette A, Salgia R, **Griffin JD**, Schaller MD. The noncatalytic domain of protein-tyrosine phosphatase-PEST targets paxillin for dephosphorylation in vivo. *J Biol Chem* 275:1405-13, 2000.
239. Gesbert F, Sellars W, **Griffin JD**. Bcr/Abl regulates expression of the cyclin dependent kinase inhibitor p27Kip-1 through the PI3K/Akt pathway. *J Biol Chem* 275:39223-30, 2000.

240. Sattler M, Verma S, Pride YB, Salgia R, Rohrschneider LR, **Griffin JD**. SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL. *J Biol Chem* 276:2451-8 2001.
241. Okuda K, Weisberg E, Gilliland DG, **Griffin JD**. ARG Tyrosine Kinase Activity is Inhibited by STI571. *Blood*, 2001 97:2440-8.
242. Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, **Griffin JD**, Johnson BE, Salgia R. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. *Oncogene*. 2000 19:3521-8.
243. Tuveson DA, Willis NA, Jacks T, **Griffin JD**, Singer S, Fletcher CDM, Jonathan A. Fletcher JA, and Demetri GD. STI-571 Inactivation of Gastrointestinal Stromal Tumor c-KIT Oncoproteins: Biological and Clinical Implications. *Oncogene*. 2001; 20:5054-8.
244. Chai Y, Wu L, **Griffin J**, and Paulson HL. The role of protein context in specifying nuclear inclusion formation in polyglutamine disease. *J Biol Chem*, 2001; 276:44889-97.
245. Bruecher-Encke B, **Griffin JD**, Neel BG, Lorenz U. Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation. *Leukemia*. 2001 9:1424-32.
246. Sattler M, Pride YB, Quinnan LR, Verma S, Malouf NA, Husson H, Salgia R, Lipkowitz S, **Griffin JD**. Differential Expression And Signaling Of Cbl And Cbl-B In Bcr/Abl Transformed Cells. *Oncogene* 21:1423-33, 2001.
247. Mow BM, Chandra J, Svingen PA, Hallgren CG, Weisberg E, Kottke TJ, Narayanan VL, Litzow MR, **Griffin JD**, Sausville EA, Tefferi A, Kaufmann SH. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. *Blood*. 2002; 99:664-71.
248. Weisberg E, Boulton C, Kelly L, Manley P, Fabbro D, Meyer T, D. Gary Gilliland DG, **Griffin JD**. Inhibition Of Mutant Flt3 Receptors In Leukemia Cells By A Small Molecule Tyrosine Kinase Inhibitor. *Cancer Cell* 1:433-43, 2002.
249. Sattler M, Golam M, Pride YB, Quinnan LR, Malouf NA, Podar K, Gesbert F, Gu H, **Griffin JD**, Neel BG. Essential role for Gab2 in transformation by BCR/ABL. *Cancer Cell* 1:479-92, 2002.
250. Wu L, Kobayashi K, **Griffin JD**. Identification of a family of transcriptional coactivators for Notch receptors. *Mol Cell Biol*. 2002:7688-700.
251. Wu L and **Griffin JD**. E6 Oncoproteins Interact with Mastermind-like Transcriptional Co-Activators and Alter Notch Signaling. Submitted, 2002.
252. Lu Q, Mukhopadhyay NK, **Griffin JD**, Paredes M, Medina M, Kosik KS. Brain armadillo protein delta-catenin interacts with Abl tyrosine kinase and modulates cellular morphogenesis in response to growth factors. *J Neurosci Res*. 67:618-24, 2002.

253. Liu S, Kiosses WB, Rose DM, Slepak M, Salgia R, **Griffin JD**, Turner CE, Schwartz MA, Ginsberg MH. A fragment of paxillin binds the alpha 4 integrin cytoplasmic domain (tail) and selectively inhibits alpha 4-mediated cell migration. *J Biol Chem.* 2002;277:20887-94.
254. Mayerhofer M, Valent P, Sperr WR, **Griffin JD**, Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. *Blood* 2002; 100:3767-75
255. Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E, Hideshima T, Lentzsch S, Davies F, Li C, Weisberg E, Schlossman RL, Richardson PG, **Griffin JD**, Wood J, Munshi NC, Anderson KC. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. *Cancer Res* 2002;62:5019-26
256. Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, Den Boer ML, Pieters R, Kersey JH, Sallan SE, Fletcher JA, Golub TR, **Griffin JD**, Korsmeyer SJ. Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification. *Cancer Cell.* 2003; 2:173-83
258. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, **Griffin JD**, Johnson BE, Salgia R. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. *Cancer Res.* 2003 Oct 1;63(19):6272-81.
257. Tonon G, Modi S, Wu L, Kubo A, Coxon AB, Komiya T, O'Neil K, Stover K, El-Naggar A, **Griffin JD**, Kirsch IR, Kaye FJ. t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. *Nat Genet.* 2003;33(2):208-13
259. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, **Griffin JD**, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. *N Engl J Med.* 2003; 348:1201-14.
260. Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM, Curley DP, Duclos N, Rowan R, Kutok JL, Lee BH, Williams IR, Coutre SE, Stone RM, DeAngelo DJ, Marynen P, Manley PW, Meyer T, Fabbro D, Neuberg D, Weisberg E, **Griffin JD**, Gilliland DG. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. *Cancer Cell.* 2003, 5:459-69
261. Sawafuji K, Miyakawa Y, Weisberg E, **Griffin JD**, Ikeda Y, Kizaki M. Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways. *Leuk Lymphoma.* 2003 Nov;44(11):1987-96.
262. Cools J, Quentmeier H, Huntly BJ, Marynen P, **Griffin JD**, Drexler HG, Gilliland DG. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRalpha-positive chronic eosinophilic leukemia. *Blood.* 2004 Apr 1;103(7):2802-5.

263. Gu TL, Tothova Z, Scheijen B, **Griffin JD**, Gilliland DG, Sternberg DW. NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. *Blood*. 2004 Jun 15;103(12):4622-9.
264. Weisberg E, Catley L, Kujawa J, Atadja P, Remiszewski S, Fuerst P, Cavazza C, Anderson K, **Griffin JD**. Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. *Leukemia*. 2004 Dec;18(12):1951-63.
265. Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, Chauhan D, Salgia R, Podar K, **Griffin JD**, Sattler M. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. *Blood*. 2004, in press.
266. Chen J, Deangelo DJ, Kutok JL, Williams IR, Lee BH, Wadleigh M, Duclos N, Cohen S, Adelsperger J, Okabe R, Coburn A, Galinsky I, Huntly B, Cohen PS, Meyer T, Fabbro D, Roesel J, Banerji L, **Griffin JD**, Xiao S, Fletcher JA, Stone RM, Gilliland DG. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. *Proc Natl Acad Sci U S A*. 2004 Oct 5;101(40):14479-84
267. Cools J, Mentens N, Furet P, Fabbro D, Clark JJ, **Griffin JD**, Marynen P, Gilliland DG. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. *Cancer Res*. 2004 Sep 15;64(18):6385-9.
268. Lin B, Catley L, Leblanc R, Mitsiades C, Burger R, Tai YT, Podar K, Wartmann M, Chauhan D, **Griffin JD**, Anderson KC. Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. *Blood*. 2005 Jan 1;105(1):350-7
269. Chen J, Wall NR, Kocher K, Duclos N, Fabbro D, Neuberg D, **Griffin JD**, Shi Y, Gilliland DG. Stable expression of small interfering RNA sensitizes TEL-PDGFBetaR to inhibition with imatinib or rapamycin. *Proc Natl Acad Sci U S A*. 2004 Oct 5;101(40):14479-84.
270. Jiang J, Paez JG, Lee JC, Bo R, Stone RM, DeAngelo DJ, Galinsky I, Wolpin BM, Jonasova A, Herman P, Fox EA, Boggon TJ, Eck MJ, Weisberg E, **Griffin JD**, Gilliland DG, Meyerson M, Sellers WR. Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. *Blood*. 2004 Sep 15;104(6):1855-8.
271. Stone RM, De Angelo J, Galinsky I, Estey E, Klimek V, Grandin W, Lebwohl D, Yap A, Cohen P, Fox E, Neuberg D, Clark J, Gilliland DG, **Griffin JD**. PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial. *Ann Hematol*. 2004;83 Suppl 1:S89-90.
272. Cowan-Jacob SW, Guez V, Fendrich G, Griffin JD, Fabbro D, Furet P, Liebetanz J, Mestan J, Manley PW. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. *Mini Rev Med Chem*. 2004 Mar;4(3):285-99.
273. Wu L, Kobayashi K, Sun T, Gao P, Liu J, Nakamura M, Weisberg E, Mukhopadhyay NK, **Griffin JD**. Cloning and functional characterization of the murine mastermind-like 1 (Maml1) gene. *Gene*. 2004 Mar 17;328:153-65.

274. Okuda K, Sato Y, Sonoda Y, **Griffin JD**. The TEL/ARG leukemia oncogene promotes viability and hyperresponsiveness to hematopoietic growth factors. *Int J Hematol*. 2004 Feb;79(2):138-46.
275. Scheijen B, Ngo HT, Kang H, **Griffin JD**. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. *Oncogene*. 2004 Apr 22;23(19):3338-49.
276. Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, **Griffin JD**, Gilliland DG, Neel BG. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. *Proc Natl Acad Sci U S A*. 2004;101:3130-5
277. Stone RM, Deangelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W, Lebwohl D, Wang Y, Cohen P, Fox EA, Neuberg D, Clark J, Gilliland DG, **Griffin JD**. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. *Blood*. 2005;105(1):54-60
278. Weisberg E, Manley PW, Breitenstein W, Brügger J, Cowan-Jacob SW, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Mohammed A, Ray A, Neuberg D, Wright RD, Gilliland DG, **Griffin JD**. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. *Cancer Cell*, 7:129-41, 2005.
279. Gowney JD, Clark JJ, Adelsperger J, Stone R, Fabbro D, **Griffin JD**, Gilliland DG. Activation mutations of human c-KIT resistant to imatinib are sensitive to the tyrosine kinase inhibitor PKC412. *Blood*. 2005, in press.
280. Mayerhofer M, Aichberger KJ, Florian S, Krauth MT, Hauswirth AW, Derdak S, Sperr WR, Esterbauer H, Wagner O, Marosi C, Pickl WF, Deininger M, Weisberg E, Druker BJ, **Griffin JD**, Sillaber C, Valent P. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. *FASEB J*. 2005, in press
281. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, **Griffin JD**, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. *Cancer Cell*. 2005 (4):387-97
282. Wu L, Liu J, Gao P, Nakamura M, Cao Y, Shen H, **Griffin JD**. Transforming activity of MECT1-MAML2 fusion oncoprotein is mediated by constitutive CREB activation. *EMBO J*. 2005 Jul 6;24(13):2391-402
283. Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW, Mestan J, Dugan M, Alland L, **Griffin JD**, Arlinghaus RB, Sun T, Kantarjian H, Beran M. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. *Clin Cancer Res*. 2005 ;11(13):4941-7.

284. Gowney JD, Clark JJ, Adelsperger J, Stone R, Fabbro D, **Griffin JD**, Gilliland DG. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. *Blood*. 2005 ;106(2):721-4.
285. Lee BH, Williams IR, Anastasiadou E, Boulton CL, Joseph SW, Amaral SM, Curley DP, Duclos N, Huntly BJ, Fabbro D, **Griffin JD**, Gilliland DG. FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model. *Oncogene*. 2005;24:7882-92.
286. Jiang J, Greulich H, Janne PA, Sellers WR, Meyerson M, **Griffin JD**. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. *Cancer Res*. 2005;65:8968-74.
287. Chen J, Lee BH, Williams IR, Kutok JL, Mitsiades CS, Duclos N, Cohen S, Adelsperger J, Okabe R, Coburn A, Moore S, Huntly BJ, Fabbro D, Anderson KC, **Griffin JD**, Gilliland DG. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. *Oncogene*. 2005;24:8259-67.
288. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, **Griffin JD**, Bernard OA, Heinrich MC, Gilliland DG, Druker B, Deininger MW. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. *Blood*. 2005;106:3377-9.
289. Stover EH, Chen J, Lee BH, Cools J, McDowell E, Adelsperger J, Cullen D, Coburn A, Moore SA, Okabe R, Fabbro D, Manley PW, Griffin JD, Gilliland DG. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. *Blood*. 2005;106:3206-13
290. Shen H, McElhinny AS, Cao Y, Gao P, Liu J, Bronson R, Griffin JD, Wu L. The Notch coactivator, MAML1, functions as a novel coactivator for MEF2C-mediated transcription and is required for normal myogenesis. *Genes Dev*. 2006,Mar 15;20(6):675-688.

Reviews, Commentaries, and Book Chapters

1. Garnick MB, **Griffin JD**, Sack MJ, Blum RH, Israel M, Frei E. Phase evaluation of N-trifluoroacetyl Adriamycin-14-valerate (AD32). In: Muggia FM, Young CW, Carter SK, eds. Anthracycline Antibiotics in Cancer Therapy. Proceedings International Symposium Anthracycline Antibiotics in Cancer Therapy. The Hague; Martinus Nijhoff, 1982; 541-8.
2. Ritz J, **Griffin JD**. Cell surface antigens in acute leukemia. In: Mihich E., ed. Biological Responses in Cancer. New York: Plenum Publishing. 1983; 1-21.
3. **Griffin JD**, Schlossman SF. Expression of myeloid differentiation antigens in myeloblastic leukemia. In: Bernard A, Boumsell L, Dausett J, Milstein C, Schlossman SF, eds. Leukocyte Typing. Berlin; Springer-Verlag, 1984: 404-410.
4. **Griffin JD**. Surface marker analysis of acute myeloblastic leukemia. In: Bloomfield CD, ed. Adult Leukemias II. The Hague: Martinus-Nijhoff, 1985; pp.113-145.
5. **Griffin JD**, Nadler LM. Surface marker analysis of chronic leukemias. In: Wiernik PH, Canellos GP, Kyle RA, Schiffer CA, eds. Neoplastic diseases of the Blood and Blood-Forming Organs. New York: Churchill-Livingstone, 1985.
6. **Griffin JD**. The application of monoclonal antibodies for the detection and classification of AML. In: Hagenbeck A and Lowenberg B, eds. Dordrecht: Martinus Nijhoff, 1986; pp. 58-67.
7. Kufe DW, **Griffin JD**, Spriggs DR. Cellular and clinical pharmacology of low-dose ara-C. Semin Oncol. 1985; 12(2 Suppl 3): 200-207 (review).
8. Linch DC, **Griffin JD**. Monoclonal antibodies reactive with myeloid cells. In: Beverly PC, ed. Monoclonal Antibodies: Methods in Hematology, Volume 13. London: Churchill Livingstone, pp. 222-246, 1986.
9. Messner HA, **Griffin JD**. Biology of Acute Myeloblastic Leukemia. Clinics in Haematology 1986; 15:641-667.
10. **Griffin JD**, Young DC. Role of colony stimulating factors in leukaemogenesis. Clinics in Haematology. 1986; 15:995-1002.
11. **Griffin JD**. Management of chronic myelogenous leukemia. Seminars in Hematology 1986; 23:20-26.
12. **Griffin JD**. The use of monoclonal antibodies in the characterization of myeloid leukemias. Hematologic Pathology 1987; 1:1-81.
13. Vellenga E, **Griffin JD**. The biology of acute myeloblastic leukemia. Seminars in Oncology 1987; 14:365-71.

14. **Griffin JD.** Clinical applications of colony-stimulating factors. *Oncology* 1988; 2:15-23.
15. Cannistra SA, **Griffin JD.** Regulation of the production and function of granulocytes and monocytes. *Semin Hematol* 1988; 25:173-88.
16. **Griffin JD.** Clinical applications of colony-stimulating factors. *Oncology* 1988; 2:15-23.
17. Demetri GD, **Griffin JD.** Hemapoietins and leukemia. *Hematol Oncol Clin North Am* 1989; 3:535-53.
18. **Griffin JD.** Hemopietins in Oncology: Factoring out myelosuppression. *J Clin Oncol* 1989; 7:151-5.
19. Ernst TJ, **Griffin JD.** Regulation of colony-stimulating factor production by normal and leukemic human cells. *Immunol Res* 1989; 8:202-14.
20. **Griffin JD,** Demetri GD, Kanakura Y, Cannistra SA, Ernst TJ. Cellular interaction regulating the production of colony-stimulating factors. *Prog Clin Biol Res* 1990; 338:129-41.
21. Demetri GD, **Griffin JD.** Hematopoietic growth factors and high-dose chemotherapy: will grams succeed where milligrams fail? *J Clin Oncol* 1990, 8:761-4.
22. Demetri GD, **Griffin JD.** Granulocyte colony stimulating factor and its receptor. *Blood* 1991; 78:2791-2808.
23. Elias AD, Mazanet R, Wheeler C, Anderson K, Ayash L, Schwartz G, Tepler I, Pap S, Pelaez J, Hunt M, Schnipper L, **Griffin JD,** Frei E, Antman K. GM-CSF potentiated peripheral blood progenitor cell (PBPC) collection with or without bone marrow as hematologic support of high-dose chemotherapy: two protocols. *Minisymposium Br Can Treatment* 1991; 20:525-529.
24. Elias AD, Mazanet R, Wheeler C, Anderson K, Ayash L, Schwartz G, Tepler I, Pap S, Gonin R, Crichtlow J, Schnipper L, **Griffin JD,** Frei E, Antman K. Peripheral blood progenitor cells (PBSC): Two protocols using GM-CSF potentiated progenitor cell collection. In Autologous Bone Marrow Transplantation. Proceedings of the Fifth International Symposium. Dicke KA, Armitage J, Dicke-Evinger MJ, eds. University of Nebraska Medical Center, Omaha, NB, 1991, pp875-880
25. **Griffin JD.** Therapeutic Uses of Hematopoietic Growth Factors in Cancer Therapy. In, Cancer, Principles and Practice of Oncology. DeVita VT, Hellman S, Rosenberg SA, eds. JB Lippencott Co, Philadelphia PA, 1996.
26. **Griffin JD.** Therapeutic Uses of Hematopoietic Growth Factors in Cancer Therapy. In, Cancer, Principles and Practice of Oncology. DeVita VT, Hellman S, Rosenberg SA, eds. JB Lippencott Co, Philadelphia PA, 2001.

27. Weisberg E and **Griffin JD**. Mechanisms of resistance to the tyrosine kinase inhibitor Glivec (STI571) in preclinical models and in leukemia patients. Drug Resistance Updates, in press, 2001.
28. Kojika S and **Griffin JD**. Notch Receptors and Hematopoiesis. Exp Hematol. 2001 9:1041-52.
29. Sattler M, **Griffin JD**. Mechanisms of transformation by the BCR/ABL oncogene. Int J Hematol. 2001 73:278-91.
30. **Griffin JD**. Point mutations in the FLT3 gene in AML. Blood. 2001 97:2193.
31. Uemura N, **Griffin JD**. The ABL kinase inhibitor STI571 does not affect survival of hematopoietic cells after ionizing radiation. Blood. 2000 96:3294-5.
32. **Griffin JD**. Phosphatidyl inositol signaling by BCR/ABL: Opportunities for drug development. Cancer Chemother Pharmacol. 2001 Suppl 1:S11-6.
33. **Griffin JD**. Leukemia stem cells and constitutive activation of NF-kappaB. Blood. 2001 98:2291A-291.
34. Gilliland DG and **Griffin JD**. Role of FLT3 in leukemia. Current Opin in Hematology 9:274-281, 2002.
35. **Griffin JD**. Resistance to targeted therapy in leukaemia. Lancet 359:458-9. 2002.
36. Scheijen B and **Griffin JD**. Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene. 2002; 21:3314-33.
37. Gilliland DG and **Griffin JD**. The roles of FLT3 in hematopoiesis and leukemia. Blood, in press, 2002.
38. Weisberg E, Griffin JD. Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Updat. 2003 Oct;6(5):231-8.
39. Sattler M, **Griffin JD**. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol. 2003 Apr;40(2 Suppl 2):4-10.
40. Griffin JD. FLT3 tyrosine kinase as a target in acute leukemias. Hematol J. 2004;5 Suppl 3:S188-90.
41. Wu L, Griffin JD. Modulation of Notch signaling by mastermind-like (MAML) transcriptional co-activators and their involvement in tumorigenesis. Semin Cancer Biol. 2004 Oct;14(5):348-56.
42. Griffin JD. Interaction maps for kinase inhibitors. Nat Biotechnol. 2005, (3):308-9.